AbbVie’s Atogepant Outperforms Topiramate in Phase III Migraine Study

AbbVie’s Phase III TEMPLE trial has met its primary endpoint, showing that atogepant, an oral CGRP receptor antagonist, led to fewer treatment discontinuations due to adverse events (12.1%) compared to topiramate (29.6%).

The double-blind, head-to-head trial involved 545 adults with episodic or chronic migraine across 73 sites in Canada, Europe, and Israel. Participants underwent a 24-week treatment period—including a six-week dose titration phase—followed by an open-label extension.

Atogepant also met all six secondary endpoints. Notably, 64.1% of patients achieved a ≥50% reduction in monthly migraine days (vs. 39.3% on topiramate). Safety and tolerability were monitored using electronic diaries and clinical assessments.

Marketed as Aquipta in the EU and Qulipta elsewhere, atogepant is approved in 60 countries for migraine prevention and has shown efficacy for both episodic and chronic cases.

23-06-2025